Risk Stratification and Outcome Prediction in Heart Failure Patients With Cardiac Implantable Electronic Devices Using Machine Learning Analysis From the HINODE Study

利用HINODE研究中的机器学习分析对植入心脏电子设备的心力衰竭患者进行风险分层和预后预测

阅读:2

Abstract

BACKGROUND: Heart failure (HF) is increasing in Japan's rapidly aging population, yet use of implantable cardioverter defibrillators and cardiac resynchronization therapy remains lower than in Western countries. Using data from HINODE, which prospectively evaluated Japanese patients with cardiac devices, we developed interpretable machine learning (ML) models to improve risk stratification and identify key predictors of adverse outcomes. METHODS AND RESULTS: Among 354 HINODE participants, 332 with adequate data were analyzed. Predictive models (XGBoost; 5-fold cross-validation) targeted HF hospitalization and all-cause mortality. Missingness was handled with multiple imputation; calibration was assessed by calibration plots and Hosmer-Lemeshow tests. Model discrimination was strong (area under the curve 0.83 and 0.85 for HF events and mortality). Shapley additive explanations (SHAP) highlighted QRS duration, QT interval, left ventricular (LV) volumes, and selected medications as major contributors. Using top SHAP features, K-means (k=2) identified low-risk (n=236) and high-risk (n=86) clusters. The high-risk cluster had larger LV volumes, wider QRS, and higher event rates. Kaplan-Meier curves showed significant differences between clusters for HF events (15.7% vs. 47.7%, log-rank P<0.001) and mortality (8.1% vs. 20.9%; hazard ratio 2.58, 95% confidence interval 1.45-4.60). Performance was temporally stable across enrollment periods. CONCLUSIONS: Interpretable ML provided accurate risk prediction and phenotype-based stratification in Japanese HF patients with cardiac devices, supporting personalized management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。